EANS-Adhoc: Epigenomics AG / Ad hoc (§15 WpHG): Epigenomics AG: Notice of Loss

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

25.03.2009

Berlin, Germany, - The Executive Board of Epigenomics AG notifies
that using its due diligence it has to be assumed that using German
GAAP HGB) accounting losses of more than half of the ordinary share
capital have been incurred. In addition to the anticipated operating
losses in the first three months of the financial year, a one-time
effect not affecting liquidity has caused reaching this threshold.
This one-time effect does not have any implications on Epigenomics'
consolidated group financials under IFRS.

In agreement with § 92 para. 1 AktG (German Stock Companies Act) the
Executive Board will summon without undue delay a general shareholder
meeting to notify all shareholders of the losses. The general meeting
to be called will according to current planning be combined with the
Company's Annual General Shareholders Meeting 2009. The Annual
General Shareholders Meeting 2009 will be held on May 11, 2009, 11:00
am CET at the premises of Deutsche Bank AG, Unter den Linden 13- 15
(Entrance Charlottenstraße), 10117 Berlin.

End of Notification

Further Information

The Executive Board will be available for questions and further
clarifying statements during the regular annual press conference and
analyst meeting 2009 that will be held on Tuesday, March 31, 2009 at
10 am to 12 noon CET at the premises of the Villa Bonn - Frankfurter
Gesellschaft für Handel Industrie und Wirtschaft in Frankfurt am Main
as well as during the regular earnings call at 3 pm on the same day
(Dial-in number within Germany: +49 868 71 790; dial-in number from
outside Germany: +1 212 444 0297)

Legal disclaimer

This communication expressly or implicitly contains certain
forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and
does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade